Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Pediatric Endocrinology

Treatment Strategies for Growth Control

At a Glance

Pituitary gigantism is usually treated first with surgery when the tumor can be removed. Medicines such as octreotide, lanreotide, or pegvisomant may be added, while radiotherapy is reserved for difficult-to-control disease because its effects and risks can be long term.

Treating pituitary gigantism is a marathon, not a sprint. Because the goal is to stop abnormal growth while protecting the brain and future health, the process usually involves several therapies. The most successful outcomes happen when care is managed by a multidisciplinary team, including pediatric endocrinologists and neurosurgeons with specific expertise in pituitary conditions [1].

First-Line Treatment: Surgery

The primary treatment for a resectable tumor is usually transsphenoidal surgery [1]. In this procedure, a surgeon removes the tumor through the nose and the sphenoid sinus, avoiding the need to open the skull [2].

  • Realistic Expectations: While surgery is an important step to reduce tumor burden and protect vision, complete biochemical cure from surgery alone is less common for large or invasive tumors. Pediatric tumors are often macroadenomas and may invade nearby areas like the cavernous sinus [3][4]. Because of this, many patients will need additional therapy to fully control their hormone levels [5][3].
  • Postoperative Risks and Care: Surgery carries risks that require close monitoring, such as cerebrospinal fluid (CSF) leaks, infection, and visual changes. A common temporary or permanent complication is diabetes insipidus, which causes excessive thirst and frequent urination. Surgery can also damage healthy pituitary tissue, causing new hormone deficiencies like adrenal insufficiency; patients must know the emergency sick-day rules for steroid replacement.

Second-Line Treatment: Medical Therapy

If surgery does not fully normalize growth hormone levels, your team will consider medications. There are two main types of drugs used, which work in very different ways. Note that some of these medications have limited long-term pediatric data and may be prescribed off-label.

Somatostatin Receptor Ligands (SRLs)

Drugs like octreotide and lanreotide (and sometimes the newer pasireotide) act like a “brake” on the tumor itself. They bind to receptors on the tumor’s surface to tell it to stop making Growth Hormone (GH) [6][7].

  • Effectiveness: These drugs can help lower GH levels and sometimes shrink the tumor [8]. However, they may be less effective in children with certain genetic markers, such as AIP mutations or X-LAG [9][10].
  • Monitoring: Doctors will monitor for side effects such as digestive upset, gallstones (via ultrasound), and changes in blood sugar (glucose) [11][12].

Growth Hormone Antagonists

Pegvisomant works differently. It does not target the tumor; instead, it blocks the growth hormone from “docking” at the liver. This prevents the liver from producing IGF-1 [13][14].

  • Effectiveness: It is often very effective at normalizing IGF-1 levels, even when other drugs fail [15][16]. However, it does not shrink the tumor and does not suppress GH secretion.
  • Monitoring: Because the tumor is still present, children on pegvisomant must have regular MRIs to ensure the tumor isn’t growing [14]. It also requires regular liver function tests to check for any signs of liver stress [17][18].

Third-Line Treatment: Radiotherapy

Radiation therapy is considered a last resort for difficult-to-control, residual disease after surgery and medications [19].

  • Modality and Timing: Options like Gamma Knife or proton beam are not interchangeable; the choice depends heavily on the tumor’s location relative to the optic nerves. The hormone-lowering effects are often delayed by years.
  • Long-Term Risks: Radiotherapy carries significant long-term risks for growing children. The most common risk is panhypopituitarism, where the radiation gradually damages the healthy parts of the pituitary gland, requiring lifelong replacement of multiple hormones [19][20]. Other rare risks, dependent on the dose and field, include neurocognitive changes or secondary tumors [21][22]. Because of these risks, your medical team will carefully weigh all options before recommending radiotherapy [1].

Common questions in this guide

What is usually the first treatment for pituitary gigantism?
For a tumor that can be removed, transsphenoidal surgery is usually the first treatment. The surgeon reaches the pituitary through the nose and sphenoid sinus rather than opening the skull. Surgery may reduce tumor size and protect vision, but larger or invasive tumors may require additional medicine.
What medicines can be used if surgery does not control pituitary gigantism?
Doctors may use medicines such as octreotide, lanreotide, or sometimes pasireotide to reduce growth hormone release. Pegvisomant works differently by blocking growth hormone's effect on the liver and lowering IGF-1; it does not shrink the tumor. Some medicines may be prescribed off-label in children, so the care team will discuss the evidence and monitoring.
What monitoring is needed with pegvisomant?
Children taking pegvisomant need regular MRI scans because the tumor remains present and the medicine does not shrink it. Regular liver function blood tests are also needed to check for liver stress. The treating pediatric endocrinology team should set the monitoring schedule.
When is radiotherapy used for pituitary gigantism?
Radiotherapy is generally reserved for disease that remains difficult to control after surgery and medicines. Gamma Knife and proton beam treatment are chosen partly according to the tumor's location relative to the optic nerves, and hormone-lowering effects may take years. In children, possible long-term loss of several pituitary hormones makes careful discussion of benefits and risks important.
What complications should families watch for after pituitary surgery?
Possible problems include a cerebrospinal fluid leak, infection, visual changes, diabetes insipidus, and new hormone deficiencies. Diabetes insipidus can cause excessive thirst and frequent urination, while adrenal insufficiency may require urgent steroid treatment. Families should learn the care team's emergency instructions, including sick-day rules and when to seek help.
Can surgery alone cure pituitary gigantism?
Surgery can be very important, but complete normalization of growth hormone is less common when the tumor is large or has invaded nearby structures such as the cavernous sinus. Additional medicine may be needed to bring hormone levels under control. The expected chance of control depends on the tumor's size, location, and response to treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was the surgery performed using a microscopic or an endoscopic approach, and how does that influence the chance of complete tumor removal?
  2. 2.Does the MRI show invasion into the cavernous sinus or contact with the optic nerves, and how does this affect our surgical cure rate?
  3. 3.If we use a medication, how will you monitor for side effects, and is the drug used off-label in children?
  4. 4.How frequently will we need liver function tests and MRIs if pegvisomant is started?
  5. 5.What are the emergency protocols for signs of a CSF leak or adrenal insufficiency after surgery?
  6. 6.What is the long-term plan for monitoring other pituitary hormones (like cortisol and thyroid hormone) after surgery or radiation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases.

    Korbonits M, Blair JC, Boguslawska A, et al.

    Nature reviews. Endocrinology 2024; (20(5)):290-309 doi:10.1038/s41574-023-00949-7.

    PMID: 38336898
  2. 2

    Outcomes of Endoscopic Transsphenoidal Approach for More Aggressive Pediatric Pituitary Adenomas: Early- and Late-Term Results from a Single Center Experience.

    Caklili M, Yilmaz E, Duman Ozturk S, et al.

    World neurosurgery 2023; (176()):e623-e633 doi:10.1016/j.wneu.2023.05.111.

    PMID: 37271260
  3. 3

    Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients.

    Rostomyan L, Daly AF, Petrossians P, et al.

    Endocrine-related cancer 2015; (22(5)):745-57 doi:10.1530/ERC-15-0320.

    PMID: 26187128
  4. 4

    Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis.

    Briceno V, Zaidi HA, Doucette JA, et al.

    Neurological research 2017; (39(5)):387-398 doi:10.1080/01616412.2017.1296653.

    PMID: 28301972
  5. 5

    Higher surgical cure of pediatric gigantism with endoscopic endonasal surgery: case series and review of the literature.

    Garton ALA, Guadix SW, Vuguin PM, et al.

    Pituitary 2026; (29(4)).

    PMID: 42538445
  6. 6

    Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.

    Ben-Shlomo A, Liu NA, Melmed S

    Pituitary 2017; (20(1)):93-99 doi:10.1007/s11102-016-0778-2.

    PMID: 27900635
  7. 7

    Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.

    Samson SL

    Neuroendocrinology 2015; (102(1-2)):8-17 doi:10.1159/000381460.

    PMID: 25792118
  8. 8

    Pituitary Gigantism in an Adolescent Girl With Postsurgical Residual Disease Treated With Lanreotide.

    Kanley AM, Bossert WL, Elrokhsi SH

    JCEM case reports 2025; (3(1)):luae225 doi:10.1210/jcemcr/luae225.

    PMID: 39678651
  9. 9

    Germline AIP variants in sporadic young acromegaly and pituitary gigantism: clinical and genetic insights from a Han Chinese cohort.

    Xiang B, Zhang X, Liu W, et al.

    Endocrine 2024; (85(3)):1346-1356 doi:10.1007/s12020-024-03898-x.

    PMID: 38851643
  10. 10

    X-linked acrogigantism syndrome: clinical profile and therapeutic responses.

    Beckers A, Lodish MB, Trivellin G, et al.

    Endocrine-related cancer 2015; (22(3)):353-67 doi:10.1530/ERC-15-0038.

    PMID: 25712922
  11. 11

    AIP expression and imaging findings in somatotroph adenomas after pre-operative lanreotide therapy for acromegaly.

    Edlmann E, Shahzad M, Yuen J, et al.

    Pituitary 2026; (29(2)).

    PMID: 41880072
  12. 12

    Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement.

    Störmann S, Meyhöfer SM, Groener JB, et al.

    Frontiers in endocrinology 2024; (15()):1348990 doi:10.3389/fendo.2024.1348990.

    PMID: 38405148
  13. 13

    Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess.

    MacFarlane J, Korbonits M

    Best practice & research. Clinical endocrinology & metabolism 2024; (38(4)):101910 doi:10.1016/j.beem.2024.101910.

    PMID: 38981769
  14. 14

    Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.

    Tritos NA, Biller BM

    Pituitary 2017; (20(1)):129-135 doi:10.1007/s11102-016-0753-y.

    PMID: 27631335
  15. 15

    Pituitary gigantism: a case series from Hospital de San José (Bogotá, Colombia).

    García WR, Cortes HT, Romero AF

    Archives of endocrinology and metabolism 2019; (63(4)):385-393 doi:10.20945/2359-3997000000150.

    PMID: 31365626
  16. 16

    Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening.

    Mangupli R, Rostomyan L, Castermans E, et al.

    Pituitary 2016; (19(5)):507-14 doi:10.1007/s11102-016-0732-3.

    PMID: 27287035
  17. 17

    Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies.

    Ma L, Luo D, Yang T, et al.

    BMC endocrine disorders 2020; (20(1)):126 doi:10.1186/s12902-020-0545-2.

    PMID: 32811475
  18. 18

    Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.

    Yuen KCJ, Vila G, Bernabeu I, et al.

    Pituitary 2026; (29(3)).

    PMID: 41984268
  19. 19

    Outcomes After Gamma Knife Stereotactic Radiosurgery in Pediatric Patients with Cushing Disease or Acromegaly: A Multi-Institutional Study.

    Shrivastava A, Mohammed N, Xu Z, et al.

    World neurosurgery 2019; (125()):e1104-e1113 doi:10.1016/j.wneu.2019.01.252.

    PMID: 30790739
  20. 20

    Predictive factors for radiation-induced pituitary damage in pediatric patients with brain tumors.

    Gorenstein L, Shrot S, Ben-Ami M, et al.

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2024; (196()):110268 doi:10.1016/j.radonc.2024.110268.

    PMID: 38641261
  21. 21

    [Secondary tumors following radiation therapy and chemotherapy : Incidence of cavernous hemangiomas].

    Reith W, Yilmaz U

    Radiologie (Heidelberg, Germany) 2023; (63(8)):603-608 doi:10.1007/s00117-023-01170-3.

    PMID: 37432425
  22. 22

    Modern Radiotherapy for Pediatric Brain Tumors.

    DeNunzio NJ, Yock TI

    Cancers 2020; (12(6)) doi:10.3390/cancers12061533.

    PMID: 32545204

This page explains treatment options for pituitary gigantism for informational purposes only and does not constitute medical advice. Discuss surgery, medicines, radiotherapy, and monitoring with your pediatric endocrinology and neurosurgery team.

Get notified when new evidence is published on Pituitary gigantism.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.